SC
ARCT icon

Sophrosyne Capital’s Arcturus Therapeutics ARCT Stock Holding History

Sophrosyne Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-22,832
Closed -$2.47M – 41
2014
Q3 		$2.47M Sell
22,832
-20,536
-47% -$2.68M 2.91% 10
2014
Q2 		$5.25M Buy
43,368
+4,331
+11% +$523K 5.35% 6
2014
Q1 		$4.96M Sell
39,037
-6,731
-15% -$998K 4.34% 7
2013
Q4 		$5.77M Buy
45,768
+29,232
+177% +$3.67M 5.05% 7
2013
Q3 		$2.09M Buy
+16,536
New +$1.47M 1.38% 25

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Sophrosyne Capital's ARCT Position: Q4 2014 in Review

Sophrosyne Capital sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 22,832 shares — an estimated $2.47M sold.

Sophrosyne Capital first reported a position in ARCT in Q3 2013 and held it in 5 quarters. The position peaked at $5.77M in Q4 2013. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Sophrosyne Capital reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 22,832 Arcturus Therapeutics shares in Q4 2014, an estimated $2.47M.
  • Sophrosyne Capital first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 5 quarters.
  • Sophrosyne Capital's Arcturus Therapeutics position peaked at $5.77M in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Sophrosyne Capital's 13F filing for Q4 2014, filed 26 Jan 2015.